V viewing financial report ｜ The new crown vaccine industry is saturated?Kangshino only earned 12.23 million in half a year, a sudden drop of 98%

Zhongxin Jingwei August 29th. The new crown vaccine industry is saturated? The 40 billion vaccine giant Kangshino's revenue and net profit in the first half of the year fell greatly.

According to the semi -annual report disclosed on the evening of the 28th, during the reporting period, the company realized operating income of about 630 million yuan, a decrease of 69.45%from the same period last year; The annual decrease of 98.69%; after the recurring profit or loss, the net loss attributable to shareholders of listed companies was 56.769 million yuan. The non -net profit of the same period last year was about 899 million yuan.

Source: Kangshino Semi -annual Report

Regarding the reason for the sharp decline in performance, Kangshino explained in the semi -annual report that it was mainly due to the slowdown of the global new crown vaccination rate during the reporting period, the decrease in vaccine demand, the new crown vaccine related inventory of vaccine products and existing signs of impairment Caused by the price.

The semi -annual report shows that Kangxino is an innovative vaccine company dedicated to research and development, production and commercialization that meets China and international standards. The company's product pipelines include 17 innovative vaccine products such as 12 indications such as Ebola virus, meningitis, new crown pneumonia, pneumonia, pneumonia, Baibaipan, tuberculosis, and shingles.

Among them, the indication is AD5-NCOV, the vaccine product of the new coronary pneumonia, that is, the reorganization of the new coronary virus vaccine (type 5 adenovirus carrier) has obtained emergency use authorization/attachment to many countries in domestic and foreign countries; AD5-NCOV has been completed. Phase/II trials of clinical I/II have conducted sequentially immune clinical trials and promoted emergency application for domestic emergency; MRNA new crown vaccine is undergoing phase IIII trials.

In terms of R & D investment, Kangshino's total investment in the first half of 2022 was about 326 million yuan, a decrease of 42.44%over the same period last year. In this regard, Kangsino said that the decline in R & D investment is mainly the company's reorganized new coronary virus vaccine (type 5 adenovirus carrier) in 2021; and the research and development stage of research and development in research and development has reduced R & D investment.

The semi-annual report shows that in the first half of 2022, the highest research and development investment was the new AD5-NCOV new crown vaccine, which invested about 159 million yuan, followed by the inhalation of the AD5-NCOV new crown vaccine, the new coronary virus MRNA vaccine, which were 50.23 million yuan and 40.321 million yuan, respectively. In the first half of the year, the R & D investment in the new crown vaccine was about 249 million yuan, accounting for about 76.38%of all R & D investment.

Public information shows that Kangshino Bio Co., Ltd. registered in Tianjin Binhai New District in 2009 with a registered capital of 156 million yuan. In March of that year, the company was listed on the main board of the Hong Kong Stock Exchange. In August 2020, it landed on the science and technology board and became the first "A+H" vaccine stock since the opening of the science and technology innovation board.

In the secondary market, Kangshino's stock price has not performed well this year. According to Flush iFind data, the price of A shares and H shares of Kangshino fell 48.66%and 67.92%during the year. On the 29th, the stock price of Cumano's A shares fell down. As of press time, it was reported at 143.65 yuan/share, a decrease of 6.59%. (Zhongxin Jingwei APP)

(The views in the article are for reference only, do not constitute investment suggestions, have risks in investment, and need to be cautious to enter the market.)

- END -